• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

Professional Introduction to Compound with CAS No. 885273-17-6 and Product Name: 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine

The compound identified by the CAS number 885273-17-6 and the product name 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine represents a significant area of interest in the field of chemical and biomedical research. This compound belongs to a class of heterocyclic amines that have garnered considerable attention due to their diverse pharmacological properties and potential applications in drug discovery. The structural framework of this molecule, featuring a 3-methoxyphenyl group and an oxazol ring system, contributes to its unique chemical and biological characteristics, making it a valuable candidate for further investigation.

In recent years, there has been a growing emphasis on the development of novel therapeutic agents that target specific biological pathways. The 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine structure has shown promise in preliminary studies as a modulator of various enzymatic and receptor interactions. Its ability to interact with biological targets at the molecular level has positioned it as a potential lead compound for the development of new medications. The presence of the 3-methoxyphenyl moiety is particularly noteworthy, as it is known to influence the electronic properties and binding affinity of the molecule, thereby enhancing its pharmacological efficacy.

One of the most compelling aspects of this compound is its potential role in addressing neurological disorders. The oxazol ring system is commonly found in bioactive molecules that exhibit neuroprotective and anti-inflammatory properties. Studies have indicated that compounds with similar structural motifs can interact with neurotransmitter systems, potentially offering therapeutic benefits in conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine molecule, with its unique combination of functional groups, may serve as a foundation for designing next-generation neuropharmacological agents.

Furthermore, the 3-methoxyphenyl group in this compound adds an additional layer of complexity that could be exploited for therapeutic purposes. This substituent is known to enhance lipophilicity and metabolic stability, which are critical factors in drug design. By optimizing the placement and electronic properties of this group, researchers can fine-tune the pharmacokinetic profile of the molecule, improving its bioavailability and reducing potential side effects. This aspect makes 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine an attractive candidate for further development in medicinal chemistry.

Recent advancements in computational chemistry have also contributed to a deeper understanding of the interactions between this compound and biological targets. Molecular docking studies have revealed that 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine can bind effectively to several key enzymes and receptors involved in disease pathways. These findings provide a strong rationale for conducting further experimental investigations to validate these computational predictions. The integration of computational methods with traditional wet-lab approaches has accelerated the drug discovery process significantly.

The synthesis of 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine presents an interesting challenge due to its complex structural features. However, modern synthetic methodologies have made it increasingly feasible to construct such molecules with high precision. Techniques such as transition-metal-catalyzed cross-coupling reactions and palladium-mediated transformations have been instrumental in achieving efficient synthetic routes. These advancements not only facilitate the production of this compound but also enable the facile introduction of structural variations for optimization purposes.

In conclusion, the compound identified by CAS number 885273-17-6 and named 2-(3-methoxyphenyl)-1,3-oxazol-4-ylmethanamine represents a promising candidate for further exploration in pharmaceutical research. Its unique structural features and demonstrated interactions with biological targets make it a valuable asset in the quest for novel therapeutic agents. As research continues to uncover new applications for this molecule, it is likely that it will play an increasingly important role in addressing some of today's most pressing medical challenges.

• 33105-96-3(4-Oxazolemethanamine,2-(4-methylphenyl)-, hydrochloride (1:1))
• 408352-90-9(1-(2-Phenyl-1,3-oxazol-4-yl)methanamine)
• 62921-39-5(Oxazole, 4-(4-methoxyphenyl)-2-phenyl-)
• 885272-93-5(2-(3-methoxyphenyl)-1,3-oxazole-4-carbaldehyde)
• 885272-69-5(4-Oxazolemethanol,2-(3-methoxyphenyl)-)
• 33105-95-2((2-phenyl-1,3-oxazol-4-yl)methylamine hydrochloride)
• 365427-22-1(Oxazole,4-ethyl-2-(3-methoxyphenyl)-)
• 154136-90-0(4-Oxazolecarboxaldehyde,2-(4-methoxyphenyl)-)
• 885272-85-5(4-Oxazolemethanamine,2-(4-aminophenyl)-)
• 885272-87-7(C-2-(4-Methoxyphenyl)oxazol-4-ylmethylamine)